Additional file 2: of Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation Da CostaElodie ArmaosGregory McInnesGabrielle BeaudryAnnie Moquin-BeaudryGaël Bertrand-LehouillierVirginie CaronMaxime RicherChantal St-OngePascal JohnsonJeffrey KroganNevan SaiYuka DowneyMichael RafeiMoutih BoileauMeaghan EppertKolja Flores-DíazEma HamanAndré HoangTrang SinnettDaniel BeauséjourChristian McGrawSerge RaynalNoël 2019 Figure S1. MYC Expression Correlates with Proscillaridin A Anticancer Efficacy. A Upper panel, half maximal inhibitory concentration (IC50) after a 24h proscillaridin A treatment (ranging from 1 nM to 100 μM) in a panel of human cancer cell lines (n=4). Lower panel, MYC protein level in each untreated cell line, assessed by western blotting. ACTIN was used as a loading control (n ≥ 3). B Graph showing MYC expression (relative to ACTIN) compared to proscillaridin A IC50 (24h) in 14 cancer cell lines. Correlation was evaluated by linear regression analysis; P-value is shown on the graph (n=3). C Representative pictures of transformed primary human fibroblasts before and after transduction with RASV12, MYC and RASV12/MYC were taken by light microscopy (400X magnification). D and E MYC expression was assessed by Western blotting in WT and MYC-transduced MOLT-4 cells (D) and REH cells (E). MYC expression was calculated as a ratio over ACTIN levels (*indicates P<0.05; One-way ANOVA; n = 3). IC50 values after 24h proscillaridin A treatment (ranging from 0.1 nM to 1 μM) in MOLT-4 cells (D) and REH cells (E) (n ≥ 3). F Time course experiment in NALM-6 cells treated with 5 nM for up to 96h. MYC expression was calculated as a ratio over ACTIN levels (*indicates P<0.05; One-way ANOVA; n = 3). (PDF 1640 kb)